Lytix Biopharma ASA to Showcase Promising Phase II Results for Ruxotemitide Combination Therapy at ASCO 2026

21 Apr 2026 16:00 CEST

Combination therapy demonstrates potential to drive durable anti-tumor responses
in difficult-to-treat cancers

Oslo, Norway, April 21 2026: Lytix Biopharma ASA (“Lytix” or the “Company”), a
clinical-stage immuno-oncology company developing novel intratumoral cancer
therapies, today announced that aggregate data analysis from its Phase II
ATLAS-IT-03 and ATLAS-IT-05 studies evaluating ruxotemitide (LTX-315) in
combination with pembrolizumab have been selected for presentation at the
American Society of Clinical Oncology (ASCO) Annual Meeting 2026, taking place
May 29 – June 2, 2026 in Chicago, Illinois.

The presentation will include data evaluating intratumoral ruxotemitide
(LTX-315) in combination with pembrolizumab in patients with unresectable
advanced melanoma who have failed to respond to anti-PD-1 or anti-PD-L1
therapies, as well as triple negative breast cancer patients that were
immunotherapy naïve.

“We are pleased that the ASCO scientific committee has selected this work for
presentation at this year’s meeting,” said Øystein Rekdal, Chief Executive
Officer of Lytix Biopharma. “These results further support the potential of
ruxotemitide in combination with pembrolizumab to induce durable anti-tumor
responses in patients with advanced melanoma and triple negative breast cancer.”

Poster Presentation Details:

Title: Safety and efficacy of intratumoral (IT) ruxotemitide (LTX 315) in
combination with pembrolizumab in patients with unresectable advanced melanoma
or triple negative breast cancer (TNBC).
Session Title: Poster Session - Developmental Therapeutics—Immunotherapy
Session Date and Time: May 30, 2026, 1:30 PM-4:30 PM CDT
Poster Number: 392

The data will be presented by Prof. Aurélien Marabelle, MD, PhD, of Gustave
Roussy, France.

Following the ASCO Annual Meeting, a copy of the poster will be made available
on the Company’s website.

About Ruxotemitide (LTX-315)
Ruxotemitide (LTX-315) is a first-in-class oncolytic peptide designed for
intratumoral administration. The molecule disrupts tumor cells locally, leading
to the release of tumor antigens and danger-associated molecular signals that
may activate systemic anti-tumor immune responses. This mechanism has the
potential to convert immunologically “cold” tumors into “hot” tumors and enhance
responses to checkpoint inhibitor therapies.

About Lytix Biopharma
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly differentiated oncolytic molecule platform based on world-leading
research in host-defense peptide-derived molecules. Lytix Biopharma’s lead
product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule
representing a new approach to maintaining durable anti-cancer immunity. Lytix
Biopharma has a pipeline of molecules that work across multiple cancer
indications and treatment settings, both as mono- and combination therapy. Lytix
is listed on Euronext Growth Oslo under the ticker LYTIX.

More information:
Access the news on Oslo Bors NewsWeb site